Abbott last week received 510(k) clearance from the US Food and Drug Administration for its self-collected molecular test for sexually transmitted infections.

Pertussis is a highly contagious acute respiratory disease that can last for several months and often causes epidemics.

Gastroenteritis is a common disease in infants and young children. The treatment of mild cases is based on the prevention and correction of dehydration, electrolyte disturbance, and acid-base imbalance, while anti-infective treatment should be considered for infants and young children with gastroenteritis that has obvious toxic symptoms and cannot be completely explained by dehydration.

Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens with no evidence of clinically manifested active TB.

Molecular diagnostics uses human saliva, tissue, blood, feces, urine, and other samples to detect disease-related markers and provides experimental diagnostic results for medical professionals in disease prevention, screening, diagnosis, stratification, prognosis, and efficacy monitoring.

The US Food and Drug Administration said Tuesday that it plans to reclassify several types of qualitative and quantitative hepatitis B virus (HBV) tests as moderate risk Class II devices from their current classification as high-risk Class III devices.

Challenge Works said Wednesday that it has awarded an £8 million prize to Sweden's Sysmex Astrego for its development of a point-of-care urinary tract infection test that delivers antibiotic susceptibility information in 45 minutes.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of 35 new wet-lab tested digital PCR Microbial DNA Detection Assays for its digital PCR (dPCR) platform QIAcuity, significantly enhancing its offerings in the field of microbial research. The new assays are available on QIAGEN’s comprehensive research platform GeneGlobe and are designed to target a wide range of pathogens responsible for tropical diseases, sexually transmitted infections (STIs) and urinary tract infections (UTIs), further solidifying QIAGEN's position as a leader in microbial detection and analysis.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAseq xHYB Mycobacterium tuberculosis Panel for research use, a new tool in the fight against tuberculosis (TB), the world’s leading infectious disease killer.

The US Food and Drug Administration last week granted Emergency Use Authorizations for two point-of-care COVID-19 and influenza combination tests developed by Sekisui Diagnostics.